Gilead Sciences (United States)

Gilead Sciences (United States)

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Gilead Sciences (United States), United States, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

59%


Total
Publications

4.6K


Total Open
Publications

2.7K


Total
Citations

200K


Open Access
Percentage

59%


Total
Publications

4.6K


Total Open
Publications

2.7K


Total
Citations

200K

Wikipedia

Website

download

Breakdown

21% 27% 11% 41%

Publisher Open

21%

Both

27%

Other Platform Open

11%

Closed

41%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

050100150200250300350400450Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

30%OA Journal

OA Journal 30%

662

Hybrid 31%

663

No Guarantees 39%

841

Other Platform Open

Domain 88%

1.5K

Institution 25%

430

Other Internet 9%

158

Public 7%

126

Preprint 6%

99

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
1.5K
Europe PMC
Domain
941
Semantic Scholar
Public
98
DOI
Other Internet
80
University of California - eScholarship University of California
Institution
53
California Digital Library - eScholarship
Other Internet
52
bioRxiv
Preprint
50
University College London - UCL Discovery
Institution
49
University of North Carolina at Chapel Hill - Carolina Digital Repository
Institution
48
Figshare
Public
37
1 / 19

Data updated 25 January 2024

Share

Share

Share